Calvin Chao

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Breast Cancer Research and Treatment · 2017 · 190 citations · Full text

Medicine, Oncology, Breast Oncology +16

Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

Hiroji Iwata, Norikazu Masuda, Yutaka Yamamoto et al. · Breast Cancer Research and Treatment · 2018 · 102 citations · Full text

Medicine, Oncology, Breast Oncology +16

12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study

Takeharu Yamanaka, Eiji Oki, Kentaro Yamazaki et al. · Journal of Clinical Oncology · 2016 · 76 citations

Medicine, Oncology, Pathology +14

The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer

Richard H. De Boer, Caroline Baker, David Speakman et al. · The Medical Journal of Australia · 2013 · 68 citations

Medicine, Oncology, Breast Oncology +16

Prospective Multicenter Study of the Impact of Oncotype DX Colon Cancer Assay Results on Treatment Recommendations in Stage II Colon Cancer Patients

Geetika Srivastava, Lindsay A. Renfro, Robert J. Behrens et al. · The Oncologist · 2014 · 65 citations · Full text

Medicine, Oncology, Pathology +16